Post-AASLD, Gilead's lead in hep C looks as solid as ever: Analysts

Now that the dust has settled after the big liver-disease meeting, analysts are handicapping the competitors in hepatitis C, current and future. The upshot? Gilead Sciences ($GILD) is likely to continue dominating the field, though it might cede some niches to newer rivals. Report